Search Results
Onco
Daily
Facebook
RSS
X
Youtube
Linkedin
October, 2024
October 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
« Sep
GU tumors
Oct 5, 2024, 16:19 |
Blog
Enrique Grande: How many challenges in GU tumors to try to address in the upcoming years?
Petros Grivas shared a post on X: "Adding a few recent Grivas Selfie examples for friends…
Jul 8, 2024, 12:07 |
Blog
Shilpa Gupta: Kudos to Philippe Spiess and Andrea Necchi on the successes of Global Society of Rare GU Tumors
Shilpa Gupta shared on X: "The amazing Philippe Spiess kicks off the session on rare…
Aug 9, 2023, 06:42 |
Blog
Great collaboration between Global Society of Rare GU tumors and International Bladder Cancer Group - Karima Oualla
Honored to be part of the fantastic Bladder Cancer Advocacy Network Think Tank, that took…
Oct 3, 2024, 07:05 |
Blog
New ESMO Clinical Practice Guideline on Rare Endocrine Tumors
ESMO posted on LinkedIn: "New ESMO Clinical Practice Guideline on Rare Endocrine Tumors: Evidence-based recommendations…
Sep 6, 2024, 15:44 |
Insight
Jerónimo Rafael Rodríguez Cid: EGFR mutated patients doesnt have any benefit with immunotherapy in TKI's resistant tumors
Jerónimo Rafael Rodríguez Cid, Medical Oncologist in CDMX, shared a post on X: "We published…
Jun 20, 2024, 11:37 |
Insight
Filippo Montemurro: Intriguing preclinical findings of synergy between fulvestrant and capecitabile in ESR1 tumors
Filippo Montemurro, Senior Medical Director at Roche, shared on X: Pure estrogen receptor antagonists potentiate…
Jun 19, 2024, 03:11 |
Insight
Andres Rodriguez Mignola: SBRT in Oligometastatic Disease in Gynecologic Tumors - A Therapeutic Option?
Andres Rodriguez Mignola, Radiation Oncologist at Ángel Roffo Institute of Oncology, shared a post on…
Jun 4, 2024, 10:39 |
Insight
Wafik El-Deiry: Good turnout by colleagues to the CNS Tumors session at ASCO24
Wafik El-Deiry recently shared on LinkedIn: “Good turnout by colleagues to the CNS Tumors session…
May 27, 2024, 04:00 |
Blog
Diego Dibitetto: H2AX downregulation is a new mechanism of chemotherapy resistance in BRCA-deficient tumors
Diego Dibitetto, Postdoc fellow at the University of Bern, shared a post on LinkedIn: "Our new…
May 21, 2024, 12:01 |
Blog
Jarushka Naidoo: Phase III trial methylphenidate versus placebo for cancer fatigue in advanced solid tumors
Jarushka Naidoo shared on X/Twitter: "Phase III trial methylphenidate versus placebo for cancer fatigue in advanced…
1
2
3
4
5
All:
730
Posts:
1 - 10
100 Influential Women in Oncology: Key Opinion Leaders to Follow on Social Media in 2024: Part 6
ASTRO24: 15 Posts Not To Miss From Day 4
Top 100 Xfluencers in Prostate Cancer: Key Opinion Leaders to follow on X (Twitter) in 2024
Paper Alert! Cutaneous Metastases in Thyroid Cancer: A Comprehensive Review of 136 Cases
ASTRO 24: 15 Posts Not to Miss From Day 3
Special Coverage
ASCO Annual Meeting
May 30 - June 4, 2024
Yvonne Award 2024
May 31, 2024
OncoThon 2024, Online
Feb. 15, 2024
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Facebook
RSS Feed
X
Linkedin
Youtube